Analyst Ratings for AMAG Pharmaceuticals (AMAG)
AMAG Rating Summary
AMAG Price Target Summary
- Highest: $23.00 (Leerink Swann)
- Lowest: $12.00 (Jefferies)
- Average: $17.75
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$17.75 (-19.1%)
Avg. $ Target:
$17.75 (-19.1%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/4/2013 | JPMorgan | Upgrade | Neutral (Underweight) |
17.00 (13.00) |
16.81 | 21.95 | 30.58% | Details |
| 1/18/2013 | Leerink Swann » Updated 3/15/2013 |
Upgrade | Outperform (Market Perform) |
23.00 (20.00) |
15.45 | 21.95 | 42.07% | Details |
| 7/27/2012 | Summer Street | Upgrade | Buy (Neutral) |
22.00 (N/A) |
15.25 | 21.95 | 43.93% | Details |
| 5/17/2012 | Ladenburg Thalmann | Upgrade | Buy (N/A) |
N/A (N/A) |
12.48 | 21.95 | 75.88% | Details |
| 5/10/2012 | Baird | Downgrade | Neutral (N/A) |
17.00 (N/A) |
14.77 | 21.95 | 48.61% | Details |
| 12/12/2011 | Goldman Sachs » Updated 5/11/2012 |
New Coverage | Neutral (N/A) |
15.50 (N/A) |
18.48 | 21.95 | 18.78% | Details |
| 11/21/2011 | Morgan Stanley | New Coverage | Equalweight (N/A) |
N/A (N/A) |
16.54 | 21.95 | 32.71% | Details |
| 4/12/2011 | Roth Capital | New Coverage | Buy (N/A) |
N/A (N/A) |
17.33 | 21.95 | 26.66% | Details |
| 2/2/2011 | Capstone Investments | Upgrade | Buy (N/A) |
N/A (N/A) |
17.75 | 21.95 | 23.66% | Details |
| 1/11/2011 | Madison Williams | Upgrade | Buy (N/A) |
N/A (N/A) |
16.69 | 21.95 | 31.52% | Details |
| 11/29/2010 | McNicoll Lewis & Vlak | Upgrade | Buy (N/A) |
N/A (N/A) |
16.80 | 21.95 | 30.65% | Details |
| 10/29/2010 | Jefferies » Updated 3/6/2012 |
Downgrade | Underperform (N/A) |
12.00 (N/A) |
16.51 | 21.95 | 32.95% | Details |
